These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34277306)

  • 1. Myasthenia Gravis as an Immune-Mediated Side Effect of Checkpoint Inhibitors.
    Heleno CT; Mustafa A; Gotera NA; Tesar A
    Cureus; 2021 Jul; 13(7):e16316. PubMed ID: 34277306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: a case report.
    Tian CY; Ou YH; Chang SL; Lin CM
    J Med Case Rep; 2021 Apr; 15(1):244. PubMed ID: 33926558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab-induced myasthenia gravis: A fatal case report.
    March KL; Samarin MJ; Sodhi A; Owens RE
    J Oncol Pharm Pract; 2018 Mar; 24(2):146-149. PubMed ID: 28147928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Checkpoint inhibitor-induced myocarditis and myasthenia gravis in a recurrent/metastatic thymic carcinoma patient: a case report.
    Szuchan C; Elson L; Alley E; Leung K; Camargo AL; Elimimian E; Nahleh Z; Sadler D
    Eur Heart J Case Rep; 2020 Jun; 4(3):1-8. PubMed ID: 32617460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myasthenia Gravis Associated With Programmed Death-1 (PD-1) Receptor Inhibitor Pembrolizumab: A 40-day Case Report.
    Ziobro AS; LaPlante RL; DeMari SR; Clark LM; Kingsley DJ; Smith AJ
    J Pharm Pract; 2021 Feb; 34(1):166-170. PubMed ID: 33143531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Case of Pembrolizumab-Induced Myasthenia Gravis.
    Kosick TI; Patel K; Jasinski J; Dada B
    Cureus; 2023 Sep; 15(9):e45455. PubMed ID: 37859893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab treatment of metastatic urothelial cancer without exacerbating myasthenia gravis.
    Ishii A; Yokoyama M; Tsuji H; Fujii Y; Tamaoka A
    eNeurologicalSci; 2020 Jun; 19():100236. PubMed ID: 32211521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors.
    Makarious D; Horwood K; Coward JIG
    Eur J Cancer; 2017 Sep; 82():128-136. PubMed ID: 28666240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab-Induced Myasthenia Gravis and Peripheral Neuropathy: A Case Series.
    McCormack SM; Hamad A
    Cureus; 2023 Sep; 15(9):e44799. PubMed ID: 37809208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab.
    Lau KH; Kumar A; Yang IH; Nowak RJ
    Muscle Nerve; 2016 Jun; 54(1):157-61. PubMed ID: 27065302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Inhibitor-Induced Myositis/Myasthenia Gravis Overlap.
    Gosser C; Al Bawaliz A; Bahaj W; Chesney J; Ranjan S
    Cureus; 2023 Nov; 15(11):e49007. PubMed ID: 38111441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab-Induced Myasthenia Gravis and Myositis: Literature Review on Neurological Toxicities of Programmed Death Protein 1 Inhibitors.
    Schwab A; Assaad M; Hamadi R; Zurndorfer J; Abi Melhem R; Holtzbach J; Loeffler J; Ibrahim M
    J Med Cases; 2022 Nov; 13(11):530-535. PubMed ID: 36506763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab-Induced Ocular Myasthenic Crisis.
    Lorenzo CJ; Fitzpatrick H; Campdesuner V; George J; Lattanzio N
    Cureus; 2020 Jul; 12(7):e9192. PubMed ID: 32685327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?
    Zaremba A; Chorti E; Jockenhöfer F; Bolz S; Sirin S; Glas M; Becker JC; Ugurel S; Roesch A; Schadendorf D; Livingstone E; Hagenacker T; Zimmer L
    J Immunother Cancer; 2019 May; 7(1):141. PubMed ID: 31142383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Checkpoint inhibitor-induced fulminant myocarditis, complete atrioventricular block and myasthenia gravis-a case report.
    Portolés Hernández A; Blanco Clemente M; Escribano García D; Velasco Calvo R; Núñez García B; Oteo Domínguez JF; Salas Antón C; Méndez García M; Segovia Cubero J; Domínguez F
    Cardiovasc Diagn Ther; 2021 Aug; 11(4):1013-1019. PubMed ID: 34527524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report.
    Kamo H; Hatano T; Kanai K; Aoki N; Kamiyama D; Yokoyama K; Takanashi M; Yamashita Y; Shimo Y; Hattori N
    BMC Neurol; 2019 Aug; 19(1):184. PubMed ID: 31382909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A case of myasthenia gravis and myositis induced by pembrolizumab].
    Noda T; Kageyama H; Miura M; Tamura T; Ito H
    Rinsho Shinkeigaku; 2019 Aug; 59(8):502-508. PubMed ID: 31341124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myasthenia gravis with myositis induced by pembrolizumab therapy in a patient with metastatic urothelial carcinoma.
    Hayakawa N; Kikuchi E; Suzuki S; Oya M
    Int Cancer Conf J; 2020 Jul; 9(3):123-126. PubMed ID: 32582515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab-induced Myasthenia Gravis: Literature Review of Ocular Manifestations and a Refractory Case.
    Dugena O; Zheng C; Taylor J; Wong A
    J Immunother; 2022 Jul-Aug 01; 45(6):267-273. PubMed ID: 35575994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma.
    Xing Q; Zhang ZW; Lin QH; Shen LH; Wang PM; Zhang S; Fan M; Zhu B
    Ann Transl Med; 2020 Mar; 8(5):250. PubMed ID: 32309397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.